Watch Ticker

Matinas BioPharma Holdings, Inc.

Go to Matinas BioPharma Holdings, Inc. Website

$0.90

0.00 (0.00%)

Live

Previous Close

$0.9

Day Range

$0 - $0

Previous Day Range

$0.88 - $0.9272

Market Cap

$4.7 million USD

Day Vol.

Previous Day Vol.

42299

Currency

USD

Primary Exchange

NYSE American, LLC

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others....

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Matinas BioPharma Holdings, Inc. - Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203, Matinas’ oral formulation of the potent antifungal amphotericin B. The patient was treated under Matinas’ Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow.

Related tickers: MTNB.

Read Full Article

Matinas BioPharma Holdings, Inc. - Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Related tickers: MTNB.

Read Full Article

Trending Tickers

Please sign in to view